Plasma CD105, TGFβ-1, TGFβ-3 and the ligand/receptor complexes in children with acute lymphoblastic leukaemia

Anticancer Research

Volumn 26, Issue 1 B, 2006, Pages 543-547

  Al Mowallad, Abdulfattah ^a   Carr, Trevor ^b   Al Qouzi, Abdullah ^a   Li, Chenggang ^a   Byers, Richard ^a,c   Kumar, Shant ^a,d  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

^c MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^d CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Acute lymphoblastic leukaemia; CD105; Ligand receptor complexes; TGF 1; TGF 3

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; BIOLOGICAL MARKER; ENDOGLIN; LIGAND; RECEPTOR PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA3; CELL SURFACE RECEPTOR; ENG PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; TGFB1 PROTEIN, HUMAN; TRANSFORMING GROWTH FACTOR BETA;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANGIOGENESIS; ARTICLE; CHILDHOOD LEUKEMIA; CONTROLLED STUDY; DRUG TARGETING; HUMAN; IMMUNOHISTOCHEMISTRY; LEUKEMOGENESIS; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; ACUTE LYMPHOCYTIC LEUKEMIA; BLOOD; CHILD; PREDICTION AND FORECASTING;

ANTIGENS, CD; CHILD; HUMANS; IMMUNOHISTOCHEMISTRY; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; LIGANDS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTORS, CELL SURFACE; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA3;

EID: 32144433712     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Smith J, Kontermann RE, Embleton J and Kumar S: Antibody phage display technologies with special reference to angiogenesis. Faseb J 19(3): 331-341, 2005.
2. Mangi MH and Newland AC: Angiogenesis and angiogenic mediators in haematological malignancies. Br J Haematol 111(1): 43-51, 2000.
3. Pule MA, Gullmann C, Dennis D, McMahon C, Jeffers M and Smith OP: Increased angiogenesis in bone marrow of children with acute lymphoblastic leukaemia has no prognostic significance. Br J Haematol 118(4): 991-998, 2002.
4. Perez-Atayde AR, Sallan SE, Tedrow U, Connors S, Allred E and Folkman J: Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol 150(3): 815-821, 1997.
5. Padro T, Ruiz S, Bieker R et al: Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood 95(5): 2637-2644, 2000.
6. Hussong JW, Rodgers GM and Shami PJ: Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood 95(1): 309-313, 2000.
7. Kini AR, Kay NE and Peterson LC: Increased bone marrow angiogenesis in B cell chronic lymphocytic leukemia. Leukemia 14(8): 1414-1418, 2000.
8. Aguayo A, Kantarjian H, Manshouri T et al: Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 96(6): 2240-2245, 2000.
9. Kumar S, Ghellal A, Li C et al: Breast carcinoma: vascular density determined using CD 105 antibody correlates with tumor prognosis. Cancer Res 59(4): 856-861, 1999.
10. Fiedler W, Graeven U, Ergun S et al: Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood 59(6): 1870-1875, 1997.
11. Aguayo A, Kantarjian HM, Estey EH et al: Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes. Cancer 95(9): 1923-1930, 2002.
12. Padro T, Bieker R, Ruiz S et al: Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia. Leukemia 16(7): 1302-1310, 2002.
13. Koomagi R, Zintl F, Sauerbrey A and Volm M: Vascular endothelial growth factor in newly diagnosed and recurrent childhood acute lymphoblastic leukemia as measured by real-time quantitative polymerase chain reaction. Clin Cancer Res 7(11): 3381-3384, 2001.
14. Yetgin S, Yenicesu I, Cetin M and Tuncer M: Clinical importance of serum vascular endothelial and basic fibroblast growth factors in children with acute lymphoblastic leukemia. Leuk Lymphoma 42(1-2): 83-88, 2001.
15. Schneider P, Vasse M, Legrand E, Callat MP and Vannier JP: Have urinary levels of the angiogenic factors, basic fibroblast growth factor and vascular endothelial growth factor, a prognostic value in childhood acute lymphoblastic leukaemia? Br J Haematol 722(7): 163-164, 2003.
16. Li C, Guo B, Bernabeu C and Kumar S: Angiogenesis in breast cancer: the role of transforming growth factor beta and CD105. Microsc Res Tech 52(4): 437-449, 2001.
17. Duff SE, Li C, Garland JM and Kumar S: CD105 is important for angiogenesis: evidence and potential applications. Faseb J 77(9): 984-992, 2003.
18. Li CG, Bethell H, Wilson PB, Bhatnagar D, Walker MG and Kumar S: The significance of CD105, TGFbeta and CD105/TGFbeta complexes in coronary artery disease. Atherosclerosis 752(7): 249-256, 2000.
19. Li C, Gardy R, Seon BK et al: Both high intratumoral microvessel density determined using CD105 antibody and elevated plasma levels of CD105 in colorectal cancer patients correlate with poor prognosis. Br J Cancer 88(9): 1424-1431, 2003.
20. Jones PH, Christodoulos K, Dobbs N et al: Combination antiangiogenesis therapy with marimastat, captopril and fragmin in patients with advanced cancer. Br J Cancer 91(1): 30-36, 2004.
21. Li C, Hampson IN, Hampson L, Kumar P, Bernabeu C and Kumar S: CD105 antagonizes the inhibitory signaling of transforming growth factor beta1 on human vascular endothelial cells. Faseb J 14(1): 55-64, 2000.
22. Lotz M, Transforming growth factor beta as endogenous growth inhibitor of chronic lymphocytic leukemia B cells. J Exp Med 179(3): 999-1004, 1994.
23. Drexler HG, Meyer C, Zaborski M, Uphoff CC and Quentmeier H: Growth-inhibitory effects of transforming growth factor-beta 1 on myeloid leukemia cell lines. Leuk Res 22(70): 927-938, 1998.
24. Piacibello W, Severino A, Stacchini A and Aglietta M: Differential effect of transforming growth factor beta 1 on the proliferation of human lymphoid and myeloid leukemia cells. Haematologica 76(6): 460-466, 1991.
25. de Caestecker MP, Piek E and Roberts AB: Role of transforming growth factor-beta signaling in cancer. J Natl Cancer Inst 92(77): 1388-1402, 2000.
26. DeCoteau JF, Knaus PI, Yankelev H et al: Loss of functional cell surface transforming growth factor beta (TGF-beta) type 1 receptor correlates with insensitivity to TGF-beta in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 94(11): 5877-5881, 1997.
27. Lagneaux L, Delforge A, Dorval C, Bron D and Stryckmans P: Excessive production of transforming growth factor-beta by bone marrow stromal cells in B-cell chronic lymphocytic leukemia inhibits growth of hematopoietic precursors and interleukin-6 production. Blood 82(8): 2379-2385, 1993.
28. Bergmann L, Schui DK, Brieger J, Weidmann E, Mitrou PS and Hoelzer D: The inhibition of lymphokine-activated killer cells in acute myeloblastic leukemia is mediated by transforming growth factor-beta 1. Exp Hematol 23(14): 1574-1580, 1995.
29. Pepper MS: Transforming growth factor-beta: vasculogenesis, angiogenesis, and vessel wall integrity. Cytokine Growth Factor Rev 8(1): 21-43, 1997.
30. Djonov V, Ball RK, Graf S et al: Transforming growth factor-beta 3 is expressed in nondividing basal epithelial cells in normal human prostate and benign prostatic hyperplasia, and is no longer detectable in prostate carcinoma. Prostate 31(2): 103-109, 1997.
31. Li C, Wang J, Wilson PB et al: Role of transforming growth factor beta3 in lymphatic metastasis in breast cancer. Int J Cancer 79(5): 455-459, 1998.
32. Fogli M, Carlo-Stella C, Curti A et al: Transforming growth factor beta3 inhibits chronic myelogenous leukemia hematopoiesis by inducing Fas-independent apoptosis. Exp Hematol 25(7): 775-783, 2000.
33. ten Dijke P, Iwata KK, Goddard C et al: Recombinant transforming growth factor type beta 3: biological activities and receptor-binding properties in isolated bone cells. Mol Cell Biol 70(9): 4473-4479, 1990.